ライフサイエンスコーパス: hazard ratio

1 was significantly longer in the BRCA mutant (hazard ratio 0.27, 95% CI 0.16-0.44, p<0.0001) and LOH h

2 elevated LMR was associated with better OS (hazard ratio 0.569, 95% confidence interval: 0.478-0.677

3 n colorectal cancer incidence rate (adjusted hazard ratio 0.57, 95% CI 0.40-0.80 for one visit; 0.51,

4 5 months (1.5-1.7) in the dacarbazine group (hazard ratio 0.62 [95% CI 0.47-0.80]; one-sided p<0.001)

5 placebo group (116 vs 163 events; stratified hazard ratio 0.73, 95% CI 0.57-0.92, p=0.0083).

6 3.3 months in the chemotherapy-alone groups (hazard ratio 0.77 [95% CI 0.62-0.95]; p=0.007).

7 sociated with graded reduction in mortality (hazard ratio 0.80, 95% CI 0.74-0.87 and 0.65, 0.60-0.71;

8 d 7.3 months (5.9-8.7) in the placebo group (hazard ratio 0.92 [95% CI 0.76-1.12], p=0.41).

9 istory (in patients with blood group A or O: hazard ratio 0.94, 95% CI 0.73-1.20, p=0.60; in all 0.91

10 e risk difference -1.4%, 95% CI -7.0 to 4.3; hazard ratio 0.96, 0.68-1.35, p=0.81).

11 up and 67% (65-69) for the sequential group (hazard ratio 0.96, 0.88-1.05; p=0.39).

12 her graft failure risks than males (adjusted hazard ratios 0-14 years: 1.51 [95% confidence intervals

13 s longer across symptom frequency subgroups (hazard ratios 0.54 [95% CI 0.34-0.86] for 0-1 symptom da

14 verted back to predicting improved survival (hazard ratio = 0.46 (95% CI: 0.26, 0.82)).

15 mokers had significantly lower risks of BCC (hazard ratio = 0.6; 95% confidence interval = 0.4-0.9) b

16 ders indicated no increase in risk (adjusted hazard ratio = 0.83, 95% confidence interval: 0.63, 1.08

17 at menarche, risk of MS was reduced by 13% (hazard ratio = 0.87, 95% confidence interval: 0.79, 0.96

18 red with those aged 18 to 24 years (adjusted hazard ratio, 0-5 years = 0.36; 6-11 = 0.29; 12-17 = 0.4

19 as compared with 535 in the ADT-alone group (hazard ratio, 0.29; 95% CI, 0.25 to 0.34; P<0.001); the

20 nd 21 events per 100 patients, respectively (hazard ratio, 0.35; 95% confidence interval [CI], 0.22 t

21 her associated with a lower intubation rate (hazard ratio, 0.42; 95% CI, 0.11-1.61; p = 0.2) nor day

22 earlier-generation fluoroquinolone (adjusted hazard ratio, 0.46 [95% confidence interval, .26-.80]) d

23 months for the placebo or observation group (hazard ratio, 0.48; 95% CI, 0.41 to 0.55).

24 ith carboplatin, 85.3%; 95% CI, 77.0%-90.8%; hazard ratio, 0.53; 95% CI, 0.29-0.96; P = .04).

25 hlorambucil led to significantly better EFS (hazard ratio, 0.54; 95% CI, 0.38 to 0.77).

26 idence than lifestyle modification patients (hazard ratio, 0.54; 95% confidence interval, 0.36-0.82).

27 l nephrectomy had reduced risk of mortality (hazard ratio, 0.55; 95% CI, 0.49 to 0.62).

28 atively similar in the unmatched population (hazard ratio, 0.57; 95% confidence interval, 0.33-0.98;

29 toward a lower risk of an appropriate shock (hazard ratio, 0.61; 95% CI, 0.33-1.12; P=0.108).

30 associated with no bystander resuscitation (hazard ratio, 0.62; 95% confidence interval [CI], 0.47 t

31 ed with a lower likelihood of ICU discharge (hazard ratio, 0.65 [0.42-1.00]; p = 0.01), longer deliri

32 34% lower in Canada than the United States (hazard ratio, 0.66 [95% CI, 0.54 to 0.81]).

33 in damage, nursing home admission, or death (hazard ratio, 0.67; 95% CI, 0.53 to 0.84).

34 ell as a lower risk of death from any cause (hazard ratio, 0.70; 95% CI, 0.50 to 0.99) and a lower ri

35 in the hazard of death after LVAD (adjusted hazard ratio, 0.73; 95% confidence interval, 0.58-0.92;

36 as associated with a significant OS benefit (hazard ratio, 0.77 [95% CI, 0.68 to 0.88]; P < .001).

37 of 158 patients (54%) in the placebo group (hazard ratio, 0.78; 95% CI, 0.57 to 1.07; P=0.12).

38 ion at 5 years relative to capping (adjusted hazard ratio, 0.78; 95% CI, 0.62-0.97; P=0.027).

39 een the 48-hour group and the 24-hour group (hazard ratio, 0.79; 95% CI, 0.54-1.15; P = .22).

40 I, 0.11-1.61; p = 0.2) nor day 28 mortality (hazard ratio, 0.80; 95% CI, 0.45-1.42; p = 0.45).

41 ndary end point (816 [5.9%] vs. 1013 [7.4%]; hazard ratio, 0.80; 95% CI, 0.73 to 0.88; P<0.001).

42 prednisolone use for exacerbation was found (hazard ratio, 0.82; 95% CI, 0.58-1.17; P = 0.28).

43 h PCI, CABG still showed a survival benefit (hazard ratio, 0.82; 95% confidence interval, 0.75-0.90;

44 262 of 9151 (2.9%) randomized to PCI alone (hazard ratio, 0.84; 95% confidence interval, 0.70-1.01;

45 4 patients [9.8%] vs. 1563 patients [11.3%]; hazard ratio, 0.85; 95% confidence interval [CI], 0.79 t

46 per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 t

47 oup and in 356 (9.3%) in the glargine group (hazard ratio, 0.91; 95% confidence interval, 0.78 to 1.0

48 rtality rates compared with whites (adjusted hazard ratio, 0.92; 95% CI, 0.76-1.11 and adjusted hazar

49 ratio, 0.92; 95% CI, 0.76-1.11 and adjusted hazard ratio, 0.92; 95% CI, 0.76-1.12, respectively).

50 interval, 0.94-1.15; P=0.46) or amlodipine (hazard ratio, 0.93; 95% confidence interval, 0.84-1.03;

51 mortality after propensity score adjustment (hazard ratio, 0.94; 95% CI, 0.89-0.99), and the benefici

52 ial effect could extend to 90-day mortality (hazard ratio, 0.95; 95% CI, 0.89-1.00).

53 nths for nivolumab versus 14 months for ICC (hazard ratio, 0.95; 95.54% CI, 0.73 to 1.24); median pro

54 .58) or the propensity score-matched cohort (hazard ratio, 0.97; 95% confidence interval, 0.64-1.47).

55 59; P=0.0006), but not of bleeding (adjusted hazard ratio, 0.99; 95% confidence interval, 0.68-1.46;

56 confidence interval, 1.06-1.24; P=0.001, and hazard ratio, 0.99; 95% confidence interval, 0.92-1.07;

57 onger activated partial thromboplastin time (hazards ratio, 0.98; p = 0.002) and decreased platelet c

58 red for 77 DCS and 136 BMS patients (12.0%) (hazard ratio: 0.54; 95% confidence interval: 0.41 to 0.7

59 s with DCM, no such difference was observed (hazard ratio: 0.92; 95% CI: 0.73 to 1.16; p = 0.49).

60 proved global longitudinal strain at 1 year (hazard ratio=0.29; P<0.001).

61 confidence interval, 0.61-0.78) and sisters hazard ratios=0.65 (95% confidence interval, 0.52-0.80),

62 bling): >/=10 cm difference between brothers hazard ratios=0.69 (95% confidence interval, 0.61-0.78)

63 n observed BMI and AF (age- and sex-adjusted hazard ratio 1.05 [1.04-1.06] per kg/m(2), P<0.001).

64 cardiovascular disease events (standardised hazard ratio 1.59, 95% CI 1.27-1.98; p<0.0001), a findin

65 n incidence of offspring lymphoid neoplasms (hazard ratio = 1.03, 95% confidence interval: 1.02, 1.04

66 ach additional experience of discrimination, hazard ratio = 1.09, 95% confidence interval: 1.01, 1.17

67 an in the antiinflammatory-stable DII group (hazard ratio = 1.32, 95% confidence interval: 1.01, 1.74

68 r categorically (for >/=2 experiences vs. 0, hazard ratio = 1.34, 95% confidence interval: 1.08, 1.66

69 erval: 1.4, 1.6) and cardiovascular disease (hazard ratio = 1.4, 95% confidence interval: 1.2, 1.6),

70 5 million/mL and all-cause hospitalizations (hazard ratio = 1.5, 95% confidence interval: 1.4, 1.6) a

71 atus was confirmed on multivariate analysis (hazard ratio = 1.694, 95% confidence interval 1.175-2.44

72 In contrast, age (hazard ratio, 1.03), a medical diagnosis (hazard ratio,

73 al MBF and clinical covariates; and adjusted hazard ratio, 1.03; 95% CI, 0.84-1.27; P=0.8 per unit de

74 alidone, randomization to either lisinopril (hazard ratio, 1.04; 95% confidence interval, 0.94-1.15;

75 ts was similar to standard ICD RPM patients (hazard ratio, 1.06; 95% confidence interval, 0.94-1.19;

76 1-U increase, P<0.001) and incident AF (FTO, hazard ratio, 1.07 [1.02-1.11] per A-allele, P=0.004; BM

77 C transfusion was not associated with death (hazard ratio, 1.07; 95% CI, 0.88-1.30; p = 0.52).

78 idence interval: 1.11, 1.33) and MELD score (hazard ratio, 1.08; 95% confidence interval: 1.06, 1.11)

79 3.1 months versus 3.7 months, respectively (hazard ratio, 1.0; 95.1% CI, 0.78 to 1.436).

80 1.11] per A-allele, P=0.004; BMI gene score, hazard ratio, 1.11 [1.05-1.18] per 1-U increase, P<0.001

81 I], -1.5 to 2.8; P=0.007 for noninferiority; hazard ratio, 1.12; 95% CI, 0.79 to 1.58; P=0.53); the u

82 for health status and psychosocial factors (hazard ratio, 1.14; 95% confidence interval, 0.96-1.35),

83 edictor of outcomes in men but not in women (hazard ratio, 1.14; 95% confidence interval, 1.06-1.24;

84 ed with post-LT survival among all patients (hazard ratio, 1.15; 95% confidence interval, 0.84-1.58)

85 he chronic phase, the effect was attenuated (hazard ratio, 1.16; 95% confidence interval, 1.08-1.25;

86 associated with increased ASD risk (adjusted hazard ratio, 1.20; 95% CI, 1.04-1.39).

87 r adjustment for competing risks, LSN score (hazard ratio, 1.22; 95% confidence interval: 1.11, 1.33)

88 th each 1-year increase in age at diagnosis (hazard ratio, 1.24; P = .0057).

89 dolinium kurtosis tended toward shorter PFS (hazard ratio, 1.30; 95% CI, 0.98-1.74 [P = 0.073]).

90 wever, the risk of hospitalization (adjusted hazard ratio, 1.34; 95% confidence interval, 1.11-1.60;

91 xperimental arm (median, 21.8 v 24.5 months; hazard ratio, 1.38; 95% CI, 0.99 to 1.94; P = .06).

92 eting risks including MELD score, LSN score (hazard ratio, 1.38; 95% confidence interval: 1.06, 1.79)

93 e (hazard ratio, 1.03), a medical diagnosis (hazard ratio, 1.43), inotrope use (hazard ratio, 3.47),

94 ed with children without asthma at baseline (hazard ratio, 1.51; 95% confidence interval, 1.08-2.10)

95 fter adjustment for all confounding factors (hazard ratio, 1.69; 95% confidence interval, 1.10-2.61;

96 ndependent prognostic factor for recurrence (hazard ratio, 1.78; P=0.005).

97 , and revascularization after scan (adjusted hazard ratio, 1.79; 95% confidence interval [CI], 1.38-2

98 en target vessel revascularization (adjusted hazard ratio, 1.82; 95% confidence interval, 1.37-2.42;

99 predicted risk for subsequent MACE (adjusted hazard ratio, 1.90; 95% confidence interval, 1.46-2.48;

100 and to have reduced rejection-free survival (hazard ratio, 1.953; 95% confidence interval, 1.234-3.09

101 was the strongest univariable PFS predictor (hazard ratio, 1.97; 95% CI, 1.44 to 2.71; P < .001).

102 to cause clotting compared with 150 mL/min (hazards ratio, 1.00 [0.60-1.69]; p = 0.68).

103 98; p = 0.002) and decreased platelet count (hazards ratio, 1.19; p = 0.03) were associated with a re

104 ing compared with use of heparin strategies (hazards ratio, 1.62; p = 0.003).

105 ity (p < 0.0005) and 1-year death and/or HF (hazard ratio: 1.27; 95% CI: 1.10 to 1.45; p = 0.001).

106 d a higher risk of bleeding hospitalization (hazard ratio=1.21; P=0.021) but a similar risk of death,

107 /=5 m/s had greater mortality risk (adjusted hazard ratio=1.86 [1.55-2.54]; P<0.001), even in the sub

108 , and the occurrence of early complications (hazard ratio, 11.34; 95% confidence interval: 1.82, 70.6

109 herapy-related myeloid neoplasm development (hazard ratio 13.7, 95% CI 1.7-108.7; p=0.013).

110 rd ratio, 4.6; 95% CI, 1.2-17.2; P = .02 and hazard ratio, 13.7; 95% CI, 2.0-91.9; P = .007, respecti

111 ns at a rate >200 beats per minute (adjusted hazard ratio, 15.63; 95% confidence interval, 4.01-60.89

112 atio, 3.47), and treatment limitation order (hazard ratio, 17.8) were all independently associated wi

113 compared with those in the lowest quartile (hazard ratio 18.4 [95% CI 9.4-36.1]).

114 D values than in those with low GARD values (hazard ratio 2.11, 95% 1.13-3.94, p=0.018).

115 -0.9) but significantly higher risks of SCC (hazard ratio = 2.3; 95% confidence interval = 1.5-3.6).

116 vels had 2.72 times the risk of miscarriage (hazard ratio = 2.72, 95% CI: 1.42-5.19) than those with

117 nts with gallstone disease vs 0.96% without; hazard ratio, 2.04; 95% confidence interval, 1.10-3.78).

118 highly associated with recurrent stroke/TIA (hazard ratio, 2.0; 95% confidence interval, 1.9-2.1).

119 nce interval, 1.11-1.60; P=0.002) and death (hazard ratio, 2.10; 95% confidence interval, 1.60-2.75;

120 sed mortality at 4 months both in allo-HSCT (hazard ratio, 2.13; 95% confidence interval, 1.45-3.13;

121 P<0.001), and cardiovascular death (adjusted hazard ratio, 2.16; 95% confidence interval, 1.36-3.43;

122 lin therapy had greater hazard of infection (hazard ratio, 2.18; 95% CI, 1.90-2.51) but no increased

123 2; P<0.0001), and stent thrombosis (adjusted hazard ratio, 2.26; 95% confidence interval, 1.42-3.59;

124 ry were because of noncardiovascular causes (hazard ratio, 2.32; 95% confidence interval, 1.92-2.81 v

125 sk of major adverse cardiac events (adjusted hazard ratio, 2.34; 95% confidence interval, 1.69-3.23;

126 creased rate of ILD-specific death (adjusted hazard ratio, 2.3; 95% confidence interval, 1.7-3.0; P <

127 dent prognostic factor for overall survival (hazard ratio, 2.480; 95% confidence interval [CI], 1.386

128 apy with TP53/KRAS comutations versus WT/WT (hazard ratio, 2.49 [95% CI, 1.10 to 5.64]; P = .03).

129 46-2.48; P<0.001), all-cause death (adjusted hazard ratio, 2.96; 95% confidence interval, 2.01-4.36;

130 associated with an increased risk of death (hazard ratio: 2.05; p < 0.0001).

131 ciated with a higher risk of major bleeding (hazard ratio: 2.19; 95% confidence interval: 1.07 to 4.4

132 subgroup of asymptomatic patients (adjusted hazard ratio=2.08 [1.25-3.46]; P=0.005).

133 [DDKT] without delayed graft function [DGF] hazard ratio: 24.634.447.9, P < 0.001; with DGF: 10.815.

134 er first-generation antipsychotics (adjusted hazard ratio, 3.06; 95% CI, 1.32-7.05) or second-generat

135 ior sclera (LD-AS decrease) reference plane (hazard ratio, 3.23; P < 0.01).

136 mab in addition to the chemotherapy regimen (hazard ratio, 3.3; 95% CI, 1.0-14.7; P = .06).

137 r second-generation antipsychotics (adjusted hazard ratio, 3.44; 95% CI, 1.73-6.83) increased the ris

138 iagnosis (hazard ratio, 1.43), inotrope use (hazard ratio, 3.47), and treatment limitation order (haz

139 -year cumulative event rates, 3.5% vs. 0.9%; hazard ratio, 3.87; 95% CI, 1.78 to 8.42; P<0.001).

140 18; P = .017), more than two initial stents (hazard ratio, 3.90; 95% confidence interval:1.16, 13.10;

141 C <25 mg/dl (2.6%) versus >/=25 mg/dl (0.8%; hazard ratio: 3.40; 95% confidence interval: 1.58 to 7.3

142 re, widowhood increased risk for AUD in men (hazard ratio=3.85, 95% CI=2.81-5.28) and women (hazard r

143 ling with AS had an exceptionally high risk (hazard ratio, 32.84) but were uncommon (34 siblings from

144 roke if warfarin treatment was discontinued (hazard ratio, 4.6; 95% CI, 1.2-17.2; P = .02 and hazard

145 with ultralow-risk patients by Cox analysis (hazard ratios, 4.73 [95% CI, 1.38-16.22] and 4.54 [95% C

146 ard ratio=3.85, 95% CI=2.81-5.28) and women (hazard ratio=4.10, 95% CI=2.98-5.64).

147 th HF with preserved ejection fraction only (hazard ratio, 5.0; P=0.001).

148 ter adjustment for traditional risk factors (hazard ratio, 5.12; 95% CI, 1.56-16.7; P = .007).

149 ater was independently associated with CAMR (hazard ratio, 5.2; P = 0.03) even when DSA was undetecte

150 4.01-60.89; P<0.0001) and >7 beats (adjusted hazard ratio, 6.26; 95% confidence interval, 2.02-19.41;

151 ring DDD-CLS and 21 (45.7%) during sham DDI (hazard ratio: 6.7; 95% CI: 2.3 to 19.8).

152 es within 3 months of medication initiation (hazard ratio=6.7, 95% CI=2.0-22.4), with similar results

153 sociated with a myeloproliferative neoplasm (hazard ratio, 8.18; 95% confidence interval: 1.45, 46.18

154 associated with ICD-treated VT/VF (adjusted hazard ratio, 9.22; 95% confidence interval, 2.53-33.60;

155 o those with no increase or increases <0.25 (hazard ratio, 9.766; 95% confidence interval [CI], 4.356

156 harge was associated with improved survival (hazard ratio [95% CI], 0.96 [0.94-0.98]), with similar f

157 c survival, with an effect-allele-attributed hazards ratio (adjusted hazards ratio) of 1.99 (95% conf

158 os were not associated with 30-day mortality hazard ratios after controlling for baseline characteris

159 re treatment was associated with an adjusted hazard ratio (aHR) for treatment failure of 20.4 (95% CI

160 with a 28% higher risk of dementia (adjusted hazard ratio [aHR], 1.28; 95% CI, 1.13-1.46) adjusted fo

161 in persons with moderate fibrosis (adjusted hazard ratio [aHR], 1.42 [95% confidence interval {CI},

162 r patients with metastatic disease (adjusted hazard ratio [AHR], 2.3; 95% CI, 1.0 to 5.1; P = .04) an

163 s had an increased hazard of death (adjusted hazard ratio [aHR], 3.13; 95% confidence interval [CI],

164 en CIT and all-cause graft failure (adjusted hazard ratio [aHR]: 1.01, 95% CI: 0.98-1.04, P = .4), de

165 s between motor function and biomarkers, and hazard ratios analyzed.

166 rd models to calculate multivariate-adjusted hazard ratios and 95% confidence intervals (CIs) for FI

167 incident cardiac events were estimated with hazard ratios and 95% confidence intervals computed in C

168 on to examining melanoma incidence, melanoma hazard ratios and 95% confidence intervals for lithium e

169 Associations were estimated by hazard ratios and 95% confidence intervals using Cox mod

170 Men had lower survival; hazard ratios and 95% confidence intervals were 1.63 (1.

171 Hazard ratios and 95% confidence intervals were estimate

172 of cigarette smoking, was used to calculate hazard ratios and 95% confidence intervals.

173 With it, the hazard ratios at older ages are considerably higher, but

174 ars of age in ARIC and REGARDS, age-adjusted hazard ratios comparing blacks versus whites were 2.61 (

175 between readmissions and hospital survival (hazard ratios: first readmission 0.88, second readmissio

176 The adjusted hazard ratio for acute rejection and all-cause mortality

177 The highest quartile hazard ratio for DDKF was 2.47 (95% confidence interval

178 s 25 months (21-31) in the once-daily group (hazard ratio for death in the once daily group 1.18 [95%

179 nusinersen group than in the control group (hazard ratio for death or the use of permanent assisted

180 -therapy group and 77% in the placebo group (hazard ratio for death, 0.57; 95% CI, 0.42 to 0.79; P=0.

181 RVD alone (50 months vs. 36 months; adjusted hazard ratio for disease progression or death, 0.65; P<0

182 independently with a higher risk of AF; the hazard ratio for each 1 SD lower SD of normal-to-normal

183 e, the three higher quartiles combined had a hazard ratio for ESRD of 1.24 (95% confidence interval [

184 ed weight loss after 1 year was related to a hazard ratio for heart failure of 0.77 (95% confidence i

185 ger varied by acuity of presentation, with a hazard ratio for MACCE in ACS patients of 0.67 (95% CI:

186 se who received CRT without a defibrillator (hazard ratio for mortality adjusted on propensity score

187 The estimated hazard ratio for overall survival in patients with follo

188 It was most favorable in terms of (1) hazard ratio for progression-free survival (0.13; 95% cr

189 The adjusted hazard ratio for publication was 1.79 (95% confidence in

190 ients of 0.67 (95% CI: 0.55 to 0.81) and the hazard ratio for SIHD patients of 0.55 (95% CI: 0.40 to

191 ose in the lowest, the multivariate-adjusted hazard ratio for T2D was 1.23 (95% confidence interval (

192 nalysis to estimate a cohort-specific causal hazard ratio for the association between BMI and AF.

193 ced AKI Network stage 2 or 3 had an adjusted hazard ratio for the primary composite outcome of 3.52 (

194 We calculated hazard ratios for 1-year adverse outcomes, including mor

195 Hazard ratios for AN were determined using Cox proportio

196 The hazard ratios for incident coronary heart disease, strok

197 uations), we compared multivariable-adjusted hazard ratios for the composite outcome of incident ASCV

198 Health, Masters et al. reported age-specific hazard ratios for the contrasts in mortality rates betwe

199 sistent remission associated with unadjusted hazard ratios for the primary outcome that ranged by lan

200 r disease-specific survival [(+)transfusion: hazard ratio (HR) 1.19, 95% confidence interval (CI) 1.0

201 treatment to significantly improve survival [hazard ratio (HR) = 0.77, 95% confidence interval (CI):

202 did not have a higher risk of breast cancer (hazard ratio (HR) = 0.95, 95% confidence interval (95% C

203 breast cancer among those with AF (adjusted hazard ratio (HR) = 1.19, 95% confidence interval (CI):

204 Increased lead (hazard ratio (HR) = 1.38; 95% confidence interval (CI):

205 CHOP) of patients having had PFS events, the hazard ratio (HR) for PFS was 0.73 (90% CI, 0.43 to 1.24

206 ional biopsy was associated with an adjusted hazard ratio (HR) of 3.0 (95% CI, 2-4.5) and, via core n

207 Compared to subjects without diabetes, hazard ratio (HR) of TKR for subjects with diabetes was

208 netics subgroups: in high-risk patients, the hazard ratio (HR) was 0.543 (95% confidence interval [CI

209 of 14.6% (95% CI, 5.7% to 23.5%); P = .014; hazard ratio (HR), 1.76 (95% CI, 1.11 to 2.79).

210 By assigning hazard ratio (HR)-weighted points to these variables, th

211 t [first quintile, referent; second quintile hazard ratio (HR)=1.03 [95% confidence interval (CI): 0.

212 We estimated hazard ratios (HR) and 95% CIs with multivariate Cox reg

213 The multivariate-adjusted hazard ratios (HR) comparing beneficiaries with statin i

214 Risk was reported in hazard ratios (HR) with 95% confidence interval (CI).

215 ardiovascular events (multivariable adjusted hazard ratio [HR(adj)]=0.75, 95% CI 0.66-0.85, p<0.0001)

216 hs [95% CI 2.8-4.2] vs 1.8 months [1.5-2.8]; hazard ratio [HR] 0.67, 95% CI 0.53-0.84, one-sided p=0.

217 ths vs 30 months in the Rd group; stratified hazard ratio [HR] 0.712, 96% CI 0.56-0.906; one-sided p

218 [95% CI 11.8-15.7] vs 9.6 months [8.6-11.2]; hazard ratio [HR] 0.73 [95% CI 0.62-0.87], p=0.0003).

219 5% CI 2.96-4.47] vs 2.76 months [2.60-2.96]; hazard ratio [HR] 0.757, 95% CI 0.607-0.943; p=0.0118).

220 end point consistently in patients with PAD (hazard ratio [HR] 0.79; 95% confidence interval [CI], 0.

221 There was no difference in overall survival (hazard ratio [HR] 1.04, 95% CI 0.90-1.19; p=0.61).

222 in the chemotherapy plus bevacizumab group (hazard ratio [HR] 1.08, 95% CI 0.91-1.29; p=0.36).

223 ] of 283) than for BUP-NX (163 [57%] of 287; hazard ratio [HR] 1.36, 95% CI 1.10-1.68), most or all o

224 from an African countries other than Egypt (hazard ratio [HR] 1.59 [95% CI 1.13-2.20]; p=0.01), hepa

225 th increased hazards of virological failure (hazard ratio [HR] 2.6, 95% CI 2.5-2.8; p<0.0001) and swi

226 nitive status (subjective cognitive decline: hazard ratio [HR] = 0.57, p < 0.05; mild cognitive impai

227 (belatacept more-intensive vs cyclosporine: hazard ratio [HR] = 0.95; 95% confidence interval [CI] 0

228 ARDs) had the highest risk of HBVr (adjusted hazard ratio [HR] = 5.14; 95% confidence interval [CI] =

229 eased incidence of hepatocellular carcinoma (hazard ratio [HR] compared with patients without an SVR,

230 and DBP, jointly suggested that, at Y0, SBP (hazard ratio [HR] per 1-SD increase, 1.32; 95% CI, 1.09-

231 Older age (hazard ratio [HR] per 10 years, 1.64; 95% CI, 1.19-2.27;

232 eline predictors of SCAF were increased age (hazard ratio [HR] per decade, 1.55; 95% CI, 1.11-2.15),

233 of 90 people with a Mars1 endotype had died (hazard ratio [HR] vs all other endotypes 1.86 [95% CI 1.

234 f the two-sided 95% CI for the local relapse hazard ratio [HR] was less than 2.03), analysed by inten

235 ion analysis, treatment with either regimen (hazard ratio [HR], 0.43; 95% confidence interval [CI], .

236 oved survival were treatment with sorafenib (hazard ratio [HR], 0.66; 95% confidence interval [CI], 0

237 ons between low IOP and time to reoperation (hazard ratio [HR], 0.73; 95% CI, 0.32-1.68), vision loss

238 icantly improved with PAG treatment overall (hazard ratio [HR], 0.73; 95% CI, 0.53 to 1.00; P = .049)

239 African Canadians (hazard ratio [HR], 0.75; 95% CI: 0.62-0.92]) and patient

240 he 2000-2004 period to the 2009-2012 period (hazard ratio [HR], 0.79; 95% CI, 0.73-0.85).

241 other potential confounders (1 cup per day: hazard ratio [HR], 0.88 [95% CI, 0.85 to 0.91]; 2 to 3 c

242 placebo + docetaxel (difference, 1.1 months; hazard ratio [HR], 0.93 [95% CI, 0.77-1.12]; P = .44).

243 ted with the appearance of any autoantibody (hazard ratio [HR], 0.98; 95% CI, 0.95-1.01), multiple is

244 therapy group vs 27.6% in the placebo group (hazard ratio [HR], 0.99 [95% CI, 0.94-1.03]) in the over

245 ficant difference in the risk of DFS events (hazard ratio [HR], 1.00; 95% CI, 0.78 to 1.28; P = 1.00)

246 ssociated with higher CSF neutrophil counts (hazard ratio [HR], 1.10 per 10% increase; 95% confidence

247 lically unhealthy non-obese (MUNO) subjects (hazard ratio [HR], 1.29; 95% confidence interval [CI], 1

248 rtality was higher for nonadherent patients (hazard ratio [HR], 1.57; 95% CI, 1.07-2.30; P < .001), a

249 sarcopenia independently predicted overall (hazard ratio [HR], 1.64; 95% CI, 1.40-1.91 and HR, 1.28;

250 95% CI, 1.06-1.25]; autism spectrum disorder hazard ratio [HR], 2.02 [95% CI, 1.80-2.26]; attention-d

251 spital Pneumonia Severity Index (PSI) class (hazard ratio [HR], 2.45, P = .027; HR, 4.23, P < .001; H

252 nalysis (MVA), pre-existing cardiac disease (hazard ratio [HR], 2.96; 95% CI, 1.07 to 8.21; P = .04)

253 inferior OS on multivariable analysis: age (hazard ratio [HR], 3.299; P < .001), white blood cell co

254 analysis showed that macrovascular invasion (hazard ratio [HR], 4.8; P < 0.001), pre-LT waiting time

255 of the composite of all-cause death and MI (hazard ratio [HR]: 0.65; 95% confidence interval [CI]: 0

256 ith reduced risks of >/=30% decline in eGFR (hazard ratio [HR]: 0.77; 95% confidence interval [CI]: 0

257 nsistent at each subsequent landmark (year 1 hazard ratio [HR]: 0.82; 95% confidence interval [CI]: 0

258 ly reduced the risk of MACE by 14% in women (hazard ratio [HR]: 0.86; 95% confidence interval [CI]: 0

259 re was associated with reductions in stroke (hazard ratio [HR]: 0.91; 95% confidence interval [CI]: 0

260 ween PCSK9 levels and the risk of mortality (hazard ratio [HR]: 1.24; 95% confidence interval [CI]: 1

261 Hazard ratios (HRs) and 95% CIs estimated using multivar

262 Hazard ratios (HRs) and 95% CIs for colorectal cancer in

263 onal hazards regression was used to estimate hazard ratios (HRs) and 95% CIs for overall survival (OS

264 Multivariable hazard ratios (HRs) and 95% confidence intervals (95%CI)

265 We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) f

266 Cox regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) f

267 We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) f

268 Cox regression models were used to calculate hazard ratios (HRs) and C statistics to determine predic

269 e used Cox models to estimate cause-specific hazard ratios (HRs) for 12 CVDs, adjusted for cardiovasc

270 h model was applied to estimate the adjusted hazard ratios (HRs) for 3 health transitions (healthy to

271 Hazard ratios (HRs) for clinical outcomes were calculate

272 Hazard ratios (HRs) for developing OAG with 95% CIs.

273 Hazard ratios (HRs) for incident parkinsonism per SD dec

274 Hazard ratios (HRs) for the diagnosis of nonaffective ps

275 s was inversely associated with incident HF: hazard ratios (HRs) of 0.99 per year (95% confidence int

276 Hazard ratios (HRs) of breast cancer were estimated usin

277 e and time-varying confounders, we estimated hazard ratios (HRs) of death and of AIDS-defining illnes

278 Hazard ratios (HRs) were calculated from time of exposur

279 Hazard ratios (HRs) with 95% confidence intervals (CIs)

280 rd analysis was used to extract the adjusted hazard ratios (HRs) with adjustments for baseline age, s

281 s (RRs) for number of deaths/recurrences and hazard ratios (HRs), with 95% confidence intervals (CI),

282 The hazard ratios [HRs] for these six factors ranged between

283 events) independently of each other, with a hazard ratio of 1.8 and 95% confidence interval of 1.1 t

284 95% confidence interval of 1.1 to 2.0, and a hazard ratio of 2.1 and 95% confidence interval of 1.3 t

285 estimate (as a continuous variable) showed a hazard ratio of 2.25 (95% confidence interval, 1.70-2.99

286 relatives of patients with AVNRT presented a hazard ratio of at least 3.6 for exhibiting AVNRT compar

287 ate Cox proportional hazards regression, the hazard ratio of HD in the first 30 days was 2.17 (95% CI

288 The hazard ratio of qSOFA score for death was 6.2 (95% CI, 3

289 ngle food frequency questionnaire, displayed hazard ratios of 1.31 (95% CI: 1.14, 1.51) and 1.07 (95%

290 The difference in hazard ratios of suicide-related events between lithium

291 ct-allele-attributed hazards ratio (adjusted hazards ratio) of 1.99 (95% confidence interval = 1.41-2

292 and incident cardiovascular disease events (hazard ratio per SD increment, 1.38; 95% confidence inte

293 al replacement therapy interaction (adjusted hazard ratio range, 0.43-0.89; p < 0.001).

294 higher mortality throughout 1-year (adjusted hazard ratio range, 1.30-1.92; p < 0.001), which was att

295 o, 0.29; 95% CI, 0.25 to 0.34; P<0.001); the hazard ratio was 0.21 in patients with nonmetastatic dis

296 ntiplatelet therapy followed for 1 year, the hazard ratio was 0.90 (0.74-1.08).

297 The unadjusted hazard ratio was 4.8 (95% confidence interval [CI] = 3.6

298 Hazard ratios were calculated per 1% increase in LGE.

299 Hazard ratios were estimated with weighted Cox regressio

300 Hazard ratios were similar for patients below or above t